Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.
Where this comes from
- Record sourced from PubMed, PMID 28973537.
- Also identified by DOI 10.1001/jamainternmed.2017.5017 and PMC identifier 5820707.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study compares the utilization, cost, and outcome data from an insurance claims database to determine the difference in treatment efficacy between the branded and compounded versions of 17-alpha hydroxyprogesterone caproate.
Medical subject headings
- 17 alpha-Hydroxyprogesterone Caproate
- Drug Costs
- Drug Utilization
- Premature Birth
- Progestins